Total trials
48
Active
30
Phase 3
0
Total enrollment
20,927
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Polypill of acetylsalicylic acid, ramipril and atorvastatin | — | — | — | — | — | 1 | |
| Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin | — | — | — | — | — | 1 | |
| Clopidogrel | — | — | — | — | — | 1 | |
| Previous treatment | — | — | — | — | — | 1 | |
| Single antiplatelet therapy | — | — | — | — | — | 1 |
Next readouts
- 2026-03-30
- 2026-10-01
- 2026-12-03
Top conditions
- Coronary Artery Disease25
- Ischemic Heart Disease18
- Coronary Artery Disease (CAD)8
- Cardiovascular Diseases6
- Coronary Disease5
- Aortic Valve Stenosis3
- Arterial Occlusive Diseases3
- Atrial Fibrillation3
Frequently asked questions about Fundación EPIC
- How many clinical trials does Fundación EPIC have on ClinicalTrials.gov?
- Fundación EPIC is listed as the lead sponsor on 48 clinical trials in ClinicalTrials.gov, 30 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fundación EPIC's trials are in Phase 3?
- 0 of Fundación EPIC's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does Fundación EPIC focus on?
- Fundación EPIC's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Ischemic Heart Disease, Coronary Artery Disease (CAD), Cardiovascular Diseases, Coronary Disease.
- When are Fundación EPIC's next clinical trial readouts?
- Fundación EPIC has 3 upcoming primary-completion readouts tracked here; the soonest is “Cross-over Study of Coronary Risk Factors With a Polypill”, expected around 2026-03-30.